Bioasis Technologies

Bioasis Technologies is a development-stage biopharmaceutical company dedicated to the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's lead program is xB3-001, an xB3 peptide carrier-trastuzumab fusion protein. It is developing xB3, a proprietary platform technology for delivering therapeutics and imaging agents across the blood-brain barrier (BBB) to address unmet medical needs in the treatment of central nervous system (CNS) diseases, including brain cancer, metabolic, and neurodegenerative disorders. The company’s internal development programs are focused on developing symptomatic and disease-modifying treatments for brain metastases, glioblastoma, and neurodegenerative diseases.